Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Evaluation of cerebral and hepatic oxidative metabolism by administration of risperidone in a subacute model in rats (Rattus norvegicus)
Evaluación del metabolismo oxidativo cerebral y hepático mediante la administración de risperidona en un modelo subagudo en ratas (Rattus norvegicus)
Avaliação do metabolismo oxidativo cerebral e hepático utilizando risperidona em um modelo subagudo em ratos (Rattus norvegicus)
DOI:
https://doi.org/10.15446/rcciquifa.v55n2.122376Palabras clave:
risperidone, oxidative stress, antioxidant enzymes, lipid peroxidation, neurotoxicity, antipsychotic (en)Risperidona, estrés oxidativo, enzimas antioxidantes, peroxidación lipídica, neurotoxicidad, antipsicótico (es)
Risperidona, estresse oxidativo, enzimas antioxidantes, peroxidação lipídica, neurotoxicidade, antipsicótico (pt)
Descargas
Objectives: this study aimed to evaluate the impact of subacute risperidone administration on antioxidant enzyme activity and lipid peroxidation in rats. Methods: a total of fifteen male Holtzman albino rats were randomly assigned to a Control group (n = 5, no risperidone) and two treatment groups (n = 5 per group) receiving 0.4 mg·kg-1·day-1 and 4.0 mg·kg-1·day-1 risperidone, administered via orogastric gavage for 20 consecutive days. After treatment, brain and liver tissues were collected. The activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glucose-6-phosphate dehydrogenase (G6PDH), and glutathione S-transferase (GST) was analyzed. Reduced glutathione (GSH) levels and lipid peroxidation, measured as thiobarbituric acid reactive substances (TBARS), were quantified. Results: findings indicate that in brain tissue, both doses significantly increased CAT activity and decreased the SOD/CAT ratio, and that the high dose significantly reduced TBARS levels. In liver tissue, a significant increase in CAT activity was observed with the high dose. Furthermore, both doses significantly increased G6PDH activity and reduced TBARS levels. Conclusions: these results underscore the influence of risperidone on cerebral and hepatic oxidative metabolism during the subacute phase.
Objetivos: este estudio tuvo como objetivo evaluar el impacto de la administración subaguda de la risperidona en la actividad de las enzimas antioxidantes y la peroxidación lipídica en ratas. Métodos: se asignaron aleatoriamente un total de quince ratas albinas Holtzman macho a un grupo Control (n = 5, sin risperidona) y dos grupos de tratamiento (n = 5 por grupo) con dosis de 0.4 mg·kg-1·día-1 y 4.0 mg·kg-1·día-1 de risperidona, administradas por vía orogástrica durante 20 días consecutivos. Después del tratamiento, se recolectaron los tejidos cerebral y hepático. Se analizó la actividad de la superóxido-dismutasa (SOD), catalasa (CAT), glutatión peroxidasa (GPx), glucosa-6-fosfato deshidrogenasa (G6PDH) y glutatión S-Transferasa (GST). Se cuantificaron los niveles de glutatión reducido (GSH) y la peroxidación lipídica, medida como sustancias reactivas al ácido tiobarbitúrico (TBARS). Resultados: los hallazgos indican que, en tejido cerebral, ambas dosis incrementaron significativamente la actividad de CAT y disminuyeron la relación SOD/CAT y que la dosis alta redujo significativamente los niveles de TBARS. En tejido hepático, se observó un aumento significativo en la actividad de CAT con la dosis alta. Asimismo, ambas dosis incrementaron significativamente la actividad de G6PDH y redujeron los niveles de TBARS. Conclusiones: estos resultados subrayan la influencia de la risperidona en el metabolismo oxidativo cerebral y hepáticodurante la fase subaguda.
Objetivos: Este estudo teve como objetivo avaliar o impacto da administração subaguda de risperidona na atividade de enzimas antioxidantes e na peroxidação lipídica em ratos. Métodos: Quinze ratos albinos Holtzman machos foram aleatoriamente alocados em um grupo controle (n = 5, sem risperidona) e dois grupos de tratamento (n = 5 por grupo) recebendo risperidona nas doses de 0,4 mg·kg⁻¹·dia⁻¹ e 4,0 mg·kg⁻¹·dia⁻¹, administradas por via orogástrica durante 20 dias consecutivos. Tecidos cerebrais e hepáticos foram coletados após o tratamento. A atividade da superóxido dismutase (SOD), catalase (CAT), glutationa peroxidase (GPx), glicose-6-fosfato desidrogenase (G6PDH) e glutationa S-transferase (GST) foi analisada. Os níveis de glutationa reduzida (GSH) e a peroxidação lipídica, medida como substâncias reativas ao ácido tiobarbitúrico (TBARS), foram quantificados. Resultados: Os achados indicam que, no tecido cerebral, ambas as doses aumentaram significativamente a atividade da CAT e diminuíram a razão SOD/CAT, e que a dose mais alta reduziu significativamente os níveis de TBARS. No tecido hepático, observou-se um aumento significativo na atividade da CAT com a dose mais alta. Da mesma forma, ambas as doses aumentaram significativamente a atividade da G6PDH e reduziram os níveis de TBARS. Conclusões: Esses resultados ressaltam a influência da risperidona no metabolismo oxidativo cerebral e hepático durante a fase subaguda.
Referencias
1. M. Turner. The role of drugs in the treatment of autism. Australian Prescriber, 43(6), 185–190 (2020). https://doi.org/10.18773/austprescr.2020.054
2. I. Kusumi, S. Boku & Y. Takahashi. Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis. Psychiatry and Clinical Neurosciences, 69(5), 243–258 (2014). https://doi.org/10.1111/pcn.12242
3. T. Sumiyoshi, H. Kido, H. Sakamoto, K. Urasaki, K. Suzuki, N. Yamaguchi, H. Mori, K. Shiba & K. Yokogawa. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacology Biochemistry and Behavior, 47(3), 553–557 (1994). https://doi.org/10.1016/0091-3057(94)90158-9
4. P. Muñoz, S. Huenchuguala, I. Paris & J. Segura-Aguilar. Dopamine oxidation and autophagy. Parkinson’s Disease, 2012, 920953 (2012). https://doi.org/10.1155/2012/920953
5. B. Halliwell & J.M.C. Gutteridge. Free Radicals in Biology and Medicine, 5th ed. Oxford University Press, New York, 2015; pp. 600-606.
6. G. Dumortier, W. Cabaret, L. Stamatiadis, G. Saba, R. Benadhira, J.F. Rocamora, B. Aubriot-Delmas, J. Glikman & D. Januel. Hepatic tolerance of atypical antipsychotic drugs. Encephale, 28(6 Pt 1), 542–551 (2002). URL: https://pubmed.ncbi.nlm.nih.gov/12506267/
7. S. Krebs, H. Dormann, U. Muth-Selbach, E.G. Hahn, K. Brune & H.T. Schneider. Risperidone-induced cholestatic hepatitis. European Journal of Gastroenterology & Hepatology, 13(1), 67–69 (2001). https://doi.org/10.1097/00042737-200101000-00013
8. S. Kumra, D. Herion, L.K. Jacobsen, C. Briguglia & D. Grothe. Case Study: Risperidone-induced hepatotoxicity in pediatric patients. Journal of the American Academy of Child & Adolescent Psychiatry, 36(5), 701–705 (1997). https://doi.org/10.1097/00004583-199705000-00022
9. E. López-Torres, Á. Süveges, E.M. Peñas-LLedó, A. Doña, P. Dorado, A. LLerena & R. Berecz. Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity. Drug Metabolism and Drug Interactions, 29(2), 123–126 (2014). https://doi.org/10.1515/dmdi-2013-0064
10. L. Mouradian-Stamatiadis, G. Dumortier, D. Januel, B.A. Delmas & W. Cabaret. Liver function tests during treatment with antipsychotic drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26(7-8), 1409–1411 (2002). https://doi.org/10.1016/s0278-5846(02)00263-4
11. A. Eftekhari, E. Ahmadian, Y. Azarmi, A. Parvizpur, H. Hamishehkar & M.A. Eghbal. In vitro/vivo studies towards mechanisms of risperidone-induced oxidative stress and the protective role of coenzyme Q10 and N-acetylcysteine. Toxicology Mechanisms and Methods, 26(7), 520–528 (2016). https://doi.org/10.1080/15376516.2016.1204641
12. A. Pillai, V. Parikh, A.V. Terry & S.P. Mahadik. Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research, 41(5), 372–386 (2007). https://doi.org/10.1016/j.jpsychires.2006.01.011
13. S. Marklund & G. Marklund. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. European Journal of Biochemistry, 47(3), 469–474 (1974). https://doi.org/10.1111/j.1432-1033.1974.tb03714.x
14. H. Aebi. Catalase in vitro. In: L. Packer (editor). Methods in Enzymology. Vol. 105. Academic Press, New York, 1984; pp. 121-126. https://doi.org/10.1016/s0076-6879(84)05016-3
15. D.E. Paglia & W.N. Valentine. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. Journal of Laboratory and Clinical Medicine, 70(1), 158–169 (1967).
16. C. Kjeldsberg, E. Beutler, C. Bell, C. Hougie, K. Foucar & R. Savage. Practical diagnosis of hematologic disorders. American Society of Clinical Pathologists Press, Chicago, 1989; p. 134.
17. W.H. Habig, M.J. Pabst & W.B. Jakoby. Glutathione S-transferases: The first enzymatic step in mercapturic acid formation. Journal of Biological Chemistry, 249(22), 7130–7139 (1974). https://doi.org/10.1016/s0021-9258(19)42083-8
18. A.F. Boyne & G.L. Ellman. A methodology for analysis of tissue sulfhydryl components. Analytical Biochemistry, 46(2), 639–653 (1972). https://doi.org/10.1016/0003-2697(72)90335-1
19. J.A. Buege & S.D. Aust. Microsomal lipid peroxidation. In: S. Fleischer & L. Packer (editors). Methods in Enzymology. Vol. 52. Academic Press, New York, 1978; pp. 302–310. https://doi.org/10.1016/s0076-6879(78)52032-6
20. A.G. Gornall, C.J. Bardawill & M.M. David. Determination of serum proteins by means of the biuret reaction. Journal of Biological Chemistry, 177(2), 751–766 (1949). https://doi.org/10.1016/s0021-9258(18)57021-6
21. National Research Council of the National Academies (US), Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals, 8th ed. The National Academies Press, Washington D.C., 2011; pp. 41–123. URL: https://grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf
22. N. Percie du Sert, A. Ahluwalia, S. Alam, M.T. Avey, M. Baker, W.J. Browne, et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biology, 18(7), e3003737 (2020). https://doi.org/10.1371/journal.pbio.3000411
23. E. Pigeolet, P. Corbisier, A. Houbion, D. Lambert, C. Michiels, M. Raes, M. Zachary & J. Remacle. Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mechanisms of Ageing and Development, 51(3), 283–297 (1990). https://doi.org/10.1016/0047-6374(90)90078-t
24. C. Cho, S. Lee, G.T. Lee, H.A. Woo, E. Choi & S.G. Rhee. Irreversible inactivation of glutathione peroxidase 1 and reversible inactivation of peroxiredoxin II by H2O2 in red blood cells. Antioxidants & Redox Signaling, 12(11), 1235–1246 (2010). https://doi.org/10.1089/ars.2009.2701
25. T. Stojković, N.V. Radonjić, M. Velimirović, G. Jevtić, V. Popović, M. Doknić & N.D. Petronijević. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 39(1), 192–199 (2012). https://doi.org/10.1016/j.pnpbp.2012.06.013
26. V. Parikh, M.M. Khan & S.P. Mahadik. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research, 37(1), 43–51 (2003). https://doi.org/10.1016/s0022-3956(02)00048-1
27. M. Casquero-Veiga, D. García-García, K.S. MacDowell, L. Pérez-Caballero, S. Torres-Sánchez, D. Fraguas, E. Berrocoso, J.C. Leza, C. Arango, M. Desco & M.L. Soto-Montenegro. Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model. European Neuropsychopharmacology, 29(7), 880–896 (2019). https://doi.org/10.1016/j.euroneuro.2019.05.002
28. F.F. Brinholi, C.C. De Farias, K.L. Bonifácio, L. Higachi, R. Casagrande, E.G. Moreira & D.S. Barbosa. Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models. Biomedicine & Pharmacotherapy, 81, 411–415 (2016). https://doi.org/10.1016/j.biopha.2016.02.047
29. C. Noto, V.K. Ota, A. Gadelha, M.N. Noto, D.S. Barbosa, K.L. Bonifácio, et al. Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone. Journal of Psychiatric Research, 68, 210–216 (2015). https://doi.org/10.1016/j.jpsychires.2015.07.003
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Licencia
Derechos de autor 2026 Revista Colombiana de Ciencias Químico-Farmacéuticas
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.
Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13
